Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

Journal for immunotherapy of cancer·2026
Same author

Ceramide-induced endoplasmic reticulum stress reveals a targetable vulnerability in endocrine therapy-resistant breast cancer.

Molecular cancer research : MCR·2026
Same author

TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens.

EMBO molecular medicine·2026
Same author

TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies.

Molecular cancer therapeutics·2026
Same author

Highlights of Tuft Cells in Mouse and Human Salivary Glands.

Cells·2026
Same author

EMBARK in biochemically recurrent prostate cancer: a journey for some but not most.

The oncologist·2026
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
See all related articles

Related Experiment Video

Updated: Jan 15, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K

MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer.

Surendra Gulla1, Tej Sharma1, Ephraim Gardner1,2

  • 1Division of Hematology and Oncology, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York.

Cancer Research
|January 13, 2026
PubMed
Summary
This summary is machine-generated.

MECOM/EVI1 drives prostate cancer progression by co-activating non-canonical androgen receptor signaling. MECOM overexpression predicts PARP inhibitor sensitivity, expanding treatment options for castrate-resistant prostate cancer.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.9K

Related Experiment Videos

Last Updated: Jan 15, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer progression involves androgen receptor (AR) cistrome reprogramming.
  • Castrate-resistant prostate cancer (CRPC) often utilizes non-canonical AR signaling resistant to AR signaling inhibitors (ARSI).

Purpose of the Study:

  • To identify factors involved in non-canonical AR signaling in CRPC.
  • To investigate the role of MECOM/EVI1 in prostate cancer.
  • To explore MECOM/EVI1 as a predictive biomarker for PARP inhibitor therapy.

Main Methods:

  • Identified EVI1 as an AR-recruited co-activator.
  • Analyzed MECOM expression in CRPC and enzalutamide-resistant CRPC.
  • Depleted MECOM in prostate cancer cells to assess effects on proliferation, survival, and super-enhancers (SEs).
  • Assessed the susceptibility of MECOM-overexpressing cells to PARP inhibitors.

Main Results:

  • MECOM was exclusively overexpressed in CRPC and enzalutamide-resistant CRPC, interacting with AR.
  • MECOM depletion reduced proliferation, altered survival pathways, decreased SEs, and increased apoptosis.
  • Cells overexpressing MECOM/EVI1 showed sensitivity to PARP inhibitors, irrespective of DNA damage response or HRR gene mutation status.

Conclusions:

  • EVI1 plays a critical role in cell survival within the AR-reprogrammed chromatin landscape of prostate cancer.
  • MECOM overexpression is a potential biomarker for broadening PARP inhibitor use beyond HRR-mutated cancers.